The synthetic development of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu®):: A challenge for synthesis & process research

被引:104
作者
Abrecht, S
Harrington, P
Iding, H
Karpf, M
Trussardi, R
Wirz, B
Zutter, U
机构
[1] F Hoffmann La Roche Ltd, Pharmaceut Div, Nonclin Dev, CH-4070 Basel, Switzerland
[2] Roche Colorado Corp, Boulder Technol Ctr, Boulder, CO 80301 USA
关键词
biotechnology; influenza neuraminidase inhibitor; process research; synthesis;
D O I
10.2533/000942904777677605
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The evolution of the synthesis of oseltamivir phosphate (Tamiflu(R)), used for the oral treatment and prevention of influenza virus infections (viral flu) is described. Oseltamivir phosphate is the ethyl ester prodrug of the corresponding acid, a potent and selective inhibitor of influenza neuraminidase. The discovery chemistry route and scalable routes used for kilo laboratory production as well as the technical access to oseltamivir phosphate from H-shikimic acid proceeding via a synthetically well-developed epoxide building block followed by azide transformations are reviewed. Synthesis and process research investigations towards azide-free conversions of the key epoxide building block to oseltamivir phosphate are discussed. The search for new routes to oseltamivir phosphate independent of shikimic acid including Diels-Alder approaches and transformations of aromatic rings employing a desymmetrization concept are presented in view of large-scale production requirements.
引用
收藏
页码:621 / 629
页数:9
相关论文
共 22 条
[21]  
VANBRUSSEL VW, 1996, BELG SPEC CHEM, V16, P142
[22]   Recent strategies in the search for new anti-influenza therapies [J].
Wilson, JC ;
von Itzstein, M .
CURRENT DRUG TARGETS, 2003, 4 (05) :389-408